title: Exposure to perinatal morphine promotes developmental changes in rat striatum.
abstract: This study shows that perinatal exposure to morphine promotes developmental changes (up to 8 months of life) in the striatum by up-regulating concentrations of substance P and met-enkephalin with changes of prometenkephalin A mRNA expression at the day of birth only. Dopamine metabolism (up to 60 days) is also increased as suggested by the reduced concentrations of dopamine and increased content of 3,4-dihydroxyphenylacetic acid. Tyrosine hydroxylase mRNA expression is selectively reduced only in the substantia nigra by perinatal morphine. Serotonin content is reduced only during the early postnatal days and is unaffected thereafter. Supplementation of naltrexone to morphine-exposed rats prevents monoaminergic and neuropeptidergic changes in the striatum, which directly implicates opioid receptors in the developmental changes caused by morphine. The data suggest that perinatal morphine may inhibit met-enkephalin release, causing accumulation of the peptide without corresponding changes in specific mRNA. Dopamine release may also be increased as indicated by a higher metabolism and consequent reduction of tyrosine hydroxylase mRNA expression in the substantia nigra.
authors.affiliation: Laboratory for Research on Pharmacology of Neurodegenerative Disorders, Department of Medical Pharmacology, Milano, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Gorio
authors.forename: M L
authors.initials: ML
authors.lastname: Malosio
authors.forename: L
authors.initials: L
authors.lastname: Vergani
authors.forename: A M
authors.initials: AM
authors.lastname: Di Giulio
mesh_terms: D015102:3,4-Dihydroxyphenylacetic Acid / Q000032:analysis / Q000378:metabolism; D000818:Animals; D004298:Dopamine / Q000032:analysis / Q000378:metabolism; D004744:Enkephalin, Methionine / Q000032:analysis; D004745:Enkephalins / Q000235:genetics; D005260:Female; D017403:In Situ Hybridization; D007774:Lactation; D008297:Male; D009020:Morphine / Q000494:pharmacology*; D009294:Narcotics / Q000494:pharmacology*; D017072:Neostriatum / Q000166:cytology / Q000187:drug effects* / Q000196:embryology*; D009474:Neurons / Q000737:chemistry / Q000187:drug effects / Q000201:enzymology; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects; D011498:Protein Precursors / Q000235:genetics; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D011957:Receptors, Opioid / Q000032:analysis; D012701:Serotonin / Q000032:analysis; D013373:Substance P / Q000032:analysis; D013569:Synapses / Q000187:drug effects; D016704:Synapsins / Q000378:metabolism; D013997:Time Factors; D014446:Tyrosine 3-Monooxygenase / Q000235:genetics
chemical_list: D004745:Enkephalins; D009294:Narcotics; D011498:Protein Precursors; D012333:RNA, Messenger; D011957:Receptors, Opioid; D016704:Synapsins; C029992:proenkephalin; D015102:3,4-Dihydroxyphenylacetic Acid; D012701:Serotonin; D013373:Substance P; D004744:Enkephalin, Methionine; D009020:Morphine; D014446:Tyrosine 3-Monooxygenase; D004298:Dopamine